Calliditas: Blockbuster Potential
Research Update
2020-03-26
07:30
Redeye strongly reiterates its positive stance on Calliditas, a high-quality biotech whose longer-term blockbuster potential should be highlighted this autumn by positive Phase III trial data for its key drug Nefecon. The recent sentiment-driven downturn has pushed the share into bear territory that underestimates Nefecon’s decent likelihood of launch.
LS
Ludvig Svensson
Disclosures and disclaimers